1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer : a Swedish population-based cohort study
- Contribution to journal › Article
- 2024
-
Mark
The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types
- Contribution to journal › Article
